C4 Therapeutics, Inc.

NasdaqGS:CCCC Stock Report

Mkt Cap: US$377.9m

We’ve recently updated our valuation analysis.

C4 Therapeutics Valuation

Is CCCC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CCCC?

Other financial metrics that can be useful for relative valuation.

CCCC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA-1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CCCC's PS Ratio compare to its peers?

The above table shows the PS ratio for CCCC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.9x
CRBU Caribou Biosciences
33.3x36.8%US$415.1m
ORGO Organogenesis Holdings
0.7x8.2%US$324.7m
ARCT Arcturus Therapeutics Holdings
10.3x40.1%US$531.6m
SRNE Sorrento Therapeutics
7.8x45.5%US$469.0m
CCCC C4 Therapeutics
7.8x61.3%US$377.9m

Price-To-Sales vs Peers: CCCC is good value based on its Price-To-Sales Ratio (7.8x) compared to the peer average (12.9x).


Price to Earnings Ratio vs Industry

How does CCCC's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Sales vs Industry: CCCC is good value based on its Price-To-Sales Ratio (7.8x) compared to the US Biotechs industry average (13x)


Price to Sales Ratio vs Fair Ratio

What is CCCC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CCCC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.8x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: CCCC is expensive based on its Price-To-Sales Ratio (7.8x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).


Share Price vs Fair Value

What is the Fair Price of CCCC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CCCC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CCCC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CCCC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.66
US$23.15
+202.3%
83.0%US$84.00US$6.00n/a13
Jan ’24US$5.90
US$23.31
+295.0%
82.0%US$84.00US$6.00n/a13
Dec ’23US$8.42
US$23.31
+176.8%
82.0%US$84.00US$6.00n/a13
Nov ’23US$10.24
US$24.15
+135.9%
78.2%US$84.00US$6.00n/a13
Oct ’23US$8.77
US$25.67
+192.7%
73.6%US$84.00US$12.00n/a12
Sep ’23US$10.14
US$25.67
+153.1%
73.6%US$84.00US$12.00n/a12
Aug ’23US$9.48
US$25.58
+169.9%
74.1%US$84.00US$10.00n/a12
Jul ’23US$8.03
US$25.67
+219.6%
73.7%US$84.00US$10.00n/a12
Jun ’23US$6.53
US$25.67
+293.1%
73.7%US$84.00US$10.00n/a12
May ’23US$8.57
US$32.67
+281.2%
67.9%US$84.00US$10.00n/a12
Apr ’23US$25.06
US$51.18
+104.2%
31.9%US$84.00US$25.00n/a11
Mar ’23US$22.76
US$52.80
+132.0%
31.8%US$84.00US$25.00n/a10
Feb ’23US$25.60
US$60.67
+137.0%
17.3%US$84.00US$44.00n/a9
Jan ’23US$32.20
US$59.67
+85.3%
14.2%US$75.00US$44.00US$5.909
Dec ’22US$34.39
US$59.67
+73.5%
14.2%US$75.00US$44.00US$8.429
Nov ’22US$45.98
US$60.00
+30.5%
14.8%US$75.00US$45.00US$10.248
Oct ’22US$45.96
US$59.00
+28.4%
15.3%US$75.00US$45.00US$8.777
Sep ’22US$42.03
US$57.83
+37.6%
8.3%US$64.00US$51.00US$10.146
Aug ’22US$43.14
US$57.50
+33.3%
8.8%US$64.00US$51.00US$9.486
Jul ’22US$38.81
US$57.50
+48.2%
8.8%US$64.00US$51.00US$8.036
Jun ’22US$37.46
US$56.50
+50.8%
6.7%US$60.00US$51.00US$6.534
May ’22US$33.10
US$56.50
+70.7%
6.7%US$60.00US$51.00US$8.574
Apr ’22US$38.63
US$56.50
+46.3%
6.7%US$60.00US$51.00US$25.064
Mar ’22US$42.39
US$48.00
+13.2%
22.3%US$60.00US$34.00US$22.763
Feb ’22US$38.05
US$42.67
+12.1%
15.5%US$50.00US$34.00US$25.603
Jan ’22US$33.13
US$43.25
+30.5%
13.4%US$50.00US$34.00US$32.204

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies